BioPharma Dive 8. Apr. 2026 Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure
BioPharma Dive 6. Apr. 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says